This pathway is activated in around 40% bladder cancer cases (FGFR3: > 10%, EGFR:> 10%, ERBB2:~ 10%, ERBB3:~ 10%, NRAS/HRAS/KRAS:~ 10%, PTEN: ~ 10%, AKT3:~ 10%) [54]. This evidence concerns the gene FGFR3 and urinary bladder carcinoma.